Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers by Lo, RCL & Ng, IOL
Title Hepatic progenitor cells: their role and functional significance inthe new classification of primary liver cancers
Author(s) Lo, RCL; Ng, IOL
Citation Liver Cancer, 2013, v. 2 n. 2, p. 84-92
Issued Date 2013
URL http://hdl.handle.net/10722/182050
Rights Creative Commons: Attribution 3.0 Hong Kong License
Review
Hepatic Progenitor Cells: Their Role 
and Functional Significance in the New 
Classification of Primary Liver Cancers
Regina Cheuk-lam Lo a Irene Oi-lin Ng a,b
aDepartment of Pathology, and bState Key Laboratory for Liver Research, The University of Hong 
Kong, Hong Kong, SAR, China
Key Words
Classification · Hepatic progenitor cells · Hepatocarcinogenesis · Hepatocellular carcinoma · 
Primary liver cancer
Abstract
Hepatic progenitor cells (HPCs) are bipotential cells residing in normal liver. Their prolifera-
tion is observed in reactive conditions of the liver and in primary liver cancers. The observa-
tion that some hepatocellular carcinomas (HCCs) express a Q1biliary-like immunophenotype 
has led to the identification of HPCs in HCC. Accumulating evidence suggests that HPCs play 
a role as the cell of origin in Q2a variety of primary liver cancers. This has led to the develop-
ment of revolutionary concepts in hepatocarcinogenesis. In this article, the role and signifi-
cance of HPCs in HCC, including its classification, are summarized and discussed.
Copyright © 2013 S. Karger AG, Basel
A Brief History of the Classification of Primary Liver Cancers
Edmondson et al. put forward a classification of primary liver cancers in 1954 in their 
paper entitled “Primary carcinoma of the liver: a study of 100 cases among 48,900 necrop-
sies” [1]. After that, it was long accepted that primary liver cancers most commonly showed 
evidence of hepatocytic or biliary differentiation, possibly derived from and recapitulating 
their respective normal counterparts. In the decades Q3following Edmondson’s landmark 
study, data accumulated that pointed to hepatocarcinogenesis being a multistep process. In 
1995, the International Working Party proposed a consensus nomenclature of hepatocellu-
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lar nodules, introducing and consolidating the concept of precursor lesions of HCC, namely 
dysplastic foci, low-grade dysplastic nodules (LGDN), and high-grade dysplastic nodules 
(HGDN) [2]. During this period, the WHO classification for HCC focused on describing the 
architectural pattern, grading, cytological variants, and some variants such as fibrolamellar 
carcinoma and sarcomatoid HCC [3].
Growing Evidence for the Presence of HPCs in HCC
Within the framework of the established classification, researchers observed some vari-
ations in terms of the differentiation of primary liver cancers, and these findings were re-
ported. In 1996, Wu et al. studied a number of primary liver cancers and found that in some 
cases, tumors histologically established as HCC expressed biliary differentiation by positive 
immunohistochemical staining for Q4AE1/3 and CK19 [4]. Kim et al. reported a series of 13 
cases in their article on primary liver carcinoma of intermediate phenotype. Morphologi-
cally, the tumors comprised “intermediate cells” with small, uniform, round-to-oval cells 
and scant cytoplasm among a fibrous stroma. Immunohistochemically, many of the tumors 
showed simultaneous expression of hepatocytic and biliary features and co-expressed c-kit 
[5]. Intermediate (hepatobiliary) cells are defined by Roskams et al. as those displaying both 
hepatocytic and biliary differentiation in diseased liver, with a size of between 6 and 40 μm, 
and showing dual immunophenotype [6].
Durnez et al. studied the immunohistochemical expression of cytokeratins CK7 and 
CK19 in 109 clinical HCC samples. The majority (72%) of cases were CK7–/CK19–, while 
6% was CK7–/CK19+, 12% CK7+/CK19–, and 10% CK7+/CK19+ [7]. CK7 and CK19 are cy-
tokeratin markers for biliary differentiation and are theoretically not expressed in normal or 
neoplastic hepatocytes. Expression of CK7 and/or CK19 in HCC suggests a biliary trait or an 
intermediate hepatocyte/HPC phenotype. These findings were echoed by a gene expression 
study in which 14 of 70 (20%) HCCs were found to have the traits of cholangiocarcinoma 
(CC) and enriched embryonic stem cell-like features [8].
The Nature of HPCs
HPCs exist in normal liver tissues in a reserved compartment. In humans, this is called 
the progenitor cell compartment and resides in the canals of Hering [6]. HPCs are referred 
to as oval cells in animal models due to their appearance under the microscope. Oval cells 
possess the potential to differentiate toward the hepatocytic or biliary phenotype. Histologi-
cally, these cells adopt the appearance of small epithelial cells with an oval nucleus and scant 
cytoplasm. Immunohistochemically, they express markers such as OV-6 and chromogranin A 
[9–11]. As reservoir cells, HPCs were shown to be activated in a wide range of liver diseases 
and in conditions such as submassive necrosis, chronic viral hepatitis, and fatty liver disease 
[9, 11–13]. The presence of HPCs in primary liver cancers therefore raised the suspicion that 
they may be implicated in hepatocarcinogenesis. Q5Related theories emerged that included 
maturation arrest and dedifferentiation as mechanisms [14]. Based on this postulation, it 
was reasonable to raise the question whether HCC precursor lesions LGDN and HGDN share 
the HPC phenotype. In fact, HPC features were identified in precursor lesions including dys-
plastic foci less than 1 mm in diameter [14], and this might fit into the multistep hepatocar-
cinogenesis model in a proportion of HCCs [15] (fig. 1a).
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The Evolution of HCC Classification
In 2009, based on the classification of hepatocellular nodules put forward by the Interna-
tional Working Party in ⌧Q6, the International Consensus Group for Hepatocellular Neoplasia 
further elaborated on the histological features of small hepatocellular nodules (<2 cm) in a 
background of cirrhosis [16]. The group also stated the five histological criteria for early HCC 
and reinstated stromal invasion as the most useful diagnostic criteria to distinguish Q7early 
HCC from HGDN. These findings were included in the latest WHO “blue book” [17]. In the 
same latest WHO classification handbook, the entity of combined hepatocellular–cholangio-
carcinoma (CHCC-CC) was illustrated and enriched in a single chapter. The histological traces 
of stem cells/progenitor cells were demonstrated in terms of morphology and immunostain-
ing. Q8CHCC-CC is believed to carry a poorer prognosis than pure HCC [17]. 
The Increasing Importance of Combined Hepatocellular–Cholangiocarcinoma 
CHCC-CC is distinct because it displays the morphological features of both HCC and CC. 
The initial theories regarding the histogenesis of this particular entity were (i)Q9 that it was 
a collision tumor, (ii) it involved dedifferentiation of a mature cell tumor; and (iii) the tumor 
originated from HPCs [18].
In a typical case of CHCC-CC, a transition/intermediate area exists between areas of clas-
sic HCC and CC. The transition areas feature small, uniform, oval-shaped cells with scant cyto-
plasm and hyperchromatic nuclei. Some other cases had tubules and cords in an “antler-like” 
pattern. Immunohistochemically, most transition areas express CK7 and CK19 in addition to 
progenitor cell markers EpCAM and c-kit [19]. Theise et al. also demonstrated that HPCs his-
tologically and immunohistochemically merge with the HCC and CC components in cases of 
CHCC-CC [20]. From the viewpoint of genetics, there was evidence from the allelic loss pattern 
that CHCC-CC represented a single clone, and that the distinct morphology was probably a 
result of divergent differentiation [21]. CHCC-CC is genetically closer to CC than to HCC, as has 
Oval cells
Hit Hit Hit
Small cell dysplasia Precancerous lesions including
low-grade and high-grade
dysplastic nodules
HCC
liver
Chronic inflammation,
leading to hepatocytic
damage and regeneration
stem cell activation
Liver stem cells Liver cancer stem cells
deregulation HCC
CC
Chronic insukts to liver such as hepatitis B & C infection,
alcohol, non-alcoholic fatty liver disease
a
b
Fig. 1. (a) Q21Schematic showing activation of progenitor cells in precursor lesions and hepatocellular car-
cinoma. (b) Model of the involvement of liver stem cells in multistep hepatocarcinogenesis.
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been shown by molecular studies investigating the loss of heterozygosity and mutations in 
p53 and β-catenin [22].
Another histological indication that primary liver cancers may originate in HPCs came 
from the study of cholangiolocellular carcinoma (CLC). CLC was first described as a subtype 
of CC. Morphologically, the tumor shows a ductular reaction-like pattern Q10within a fibrous 
stroma. Immunophenotypically, CLC shows cholangiocellular differentiation with expres-
sion of CK7 and CK19. What makes CLC distinct is the co-expression of neural cell adhesion 
molecule (NCAM), an HPC marker. In a recent case series of 30 CLCs, a component of classic 
HCC was identified in all cases [23]. CLC has been described in the latest WHO “blue book” as 
“combined hepatocellular–cholangiocarcinoma with stem-cell features, cholangiolocellular 
type” [17].
The Prognostic Significance of the HPC Signature in HCC
Q11Multiple studies have shown that the HPC signature is associated with poor prog-
nosis in patients with HCC [24, 25]. In a cohort study of 137 human HCCs by Kim et al. [26], 
the immunohistochemical expression rates of CK19, EpCAM, c-kit, and CD133 were 18.2%, 
35.0%, 34.3%, and 24.8%, respectively. In a second cohort of 237 HCC cases, CK19+ cases 
were associated with more frequent microvascular invasion, less frequent capsule forma-
tion, and a fibrous stroma; CK19 expression was an independent prognostic factor for dis-
ease-free survival after tumor resection in this cohort [26].
Others have demonstrated that expression of AE1/3 and CK19 in HCC correlated with 
poorer cellular differentiation, Q12⌧ proliferative marker index, and poor survival [4]. It has 
also been reported that, after liver transplantation, CK19 expression is associated with a 
higher rate of recurrence compared to CK19– tumors [7]. In a gene expression study, a chol-
angiocarcinoma-like trait was an independent prognostic factor in HCC [8].
The prognostic significance of HPC markers extends beyond tumor tissues. Non-tumor-
al ductular reaction and its proliferative index, which signifies HPC activation, were inde-
pendent prognostic factors for overall and disease-free survival in CHCC-CC patients after 
resection [27]. In addition, soluble NCAM in patient sera was shown to be associated with 
poor prognosis [28].
There have also been studies indicating that the presence of HPCs in chronic liver dis-
eases predicts HCC occurrence. The frequency of expression of stem cell markers was found 
to correlate with the frequency of HCC arising in the background of various chronic liver 
diseases such as HBV, HCV, alcoholic steatohepatitis, and non-alcoholic steatohepatitis [29]. 
Ziol et al. prospectively studied the expression of progenitor cell markers in a cohort of 150 
HCV-related cirrhotic liver biopsy cases and found that immunohistochemical expression of 
intermediate cell markers was associated independently with the occurrence of HCC [30].
Supporting Evidence from Basic Research on the Role of HPCs in HCC
In recent years, the study of cancer stem cells (CSCs) or tumor-initiating cells (TICs) in 
HCC has been a hot topic of basic research, Q13and many results and much data have recently 
been published. HPCs, first characterized histologically under a microscope, are believed to 
represent liver stem cells. Upon genetic deregulation of the self-renewal pathway, HPC/liver 
stem cells may transform into CSCs or TICs that drive tumor initiation [31] (fig. 1b). The 
characteristics of CSCs in HCC have been reviewed by Chiba et al. [32], and the various mark-
ers of liver TICs have been summarized by our group [33] (table 1). These studies will help 
our understanding of how HPCs play a role in the tumorigenesis of HCC. 
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Characterization of HPCs/CSCs in HCC Cell Lines
In 2006, Chiba et al. identified CSC-like properties in HCC cell lines by means of side-
population cell analysis and sorting analysis [34]. In the same year, Haraguchi et al. identified 
and characterized stem cells in HCC cell lines [35]. The tumorigenic role of HPCs/stem-cell-
marker-positive cells has been demonstrated. The EpCAM+ population among HCC cell lines 
confers a higher tumorigenic activity [36]. EpCAM+ cells showed a higher ability to self-renew 
and differentiate and were capable of higher tumorigenicity [37]. CD133+ cells in the Huh7 
cell line have higher proliferative potential in vitro and higher tumorigenic activity in vivo 
[38]. In addition, in HCC cell lines, CD133+ cells have a higher tumorigenicity and clonogenic-
ity than CD133– cells do [39]. OV6+ TICs exhibited greater potential in terms of invasiveness and metastasis in in vivo and in vitro studies [40].
Dissecting Heterogeneous Liver Cancer Stem Cells
Given the vast number of cancer stem cell markers identified in HCC, recent research 
has suggested heterogeneity in liver cancer stem cells (L-CSCs); a large amount of work on 
further categorization according to expression profiles has been carried out. Some results 
have confirmed that subgroups of L-CSCs, in terms of expression of markers, possess more 
pronounced “stemness” features, including the ability to proliferate and generate tumors and 
to confer increased chemoresistance. For example, CD133+/CD44+ HCC cells displayed high-
er clonogenicity in vitro, higher tumorigenicity in vivo, and higher chemoresistance than the 
CD133+/CD44– subgroup did [41]. CD90+/CD44+ L-CSCs behaved more aggressively than 
CD90+/CD44– L-CSCs did [42]. These findings, while requiring more supporting data, pos-
sibly provide some enlightenment on the choice of targeted therapy to deliver the most cost-
effective treatment regimen.
Table 1. Summary of TIC/CSC markers for therapeutic purpose
TIC/CSC markers Inhibitors
CD13 CD13 inhibitor ubenimex, anti-CD13 antibody
CD24 Anti-CD24 antibody
CD44 Anti-CD44 antibody, RNA interference, antisense oligonucleotides
CD90 Anti-CD90 antibody
CD133 Anti-CD133 antibody, lupeol, antisense oligonucleotides
DLK1 RNA interference targeting DLK1
EpCAM Bispecific antibody EpCAMxCD3, RNA interference, GSK-3β inhibitor BIO
GEP Anti-GEP antibody, RNA interference
OV6 RNA interference targeting β-catenin
SP RNA interference targeting BMI-1
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Regulations and Signaling Pathways of L-CSC
The signaling pathways through which L-CSCs maintain and exert their properties have 
been summarized [37, 43]. Q15While signaling is not explicitly discussed in this article, some 
examples will help to introduce the scope of this topic. It has been proposed that the con-
trol of stem cell proliferation is associated with Notch, Wnt, and TGF-β signaling pathways 
[44]. In addition, TP53-mutated tumors have been shown to be associated with expression 
of stem cell markers CD24 and AFP [45].
Perspectives
Further understanding of the role of HPCs in the tumorigenesis of HCC will help to strat-
ify patients with chronic liver diseases according to their chances of developing HCC, as well 
as adding prognostication information for patients who have already developed HCC. Tar-
geted therapy for patients with precursor or malignant lesions expressing HPC signatures 
may possibly lower the risk of HCC development and progression, respectively. ItQ16 may 
also shed light on altering the high chemoresistance of HCC to conventional systemic che-
motherapy. In terms of histological classification of primary liver cancers, it has been sug-
gested that a proportion of tumors that display intermediate features or stem/progenitor 
cell phenotypes according to morphological and immunohistochemical criteria should be 
labeled  “mixed hepatobiliary carcinomas” [46]. This upcoming classification will hopefully 
simplify the picture and reflect the constantly emerging data from studies on the differentia-
tion lineage of HCC (fig. 2).
Phenotype Immunophenotype Nomenclature
HCC
HCC
Both HCC & CC components
(usually with intermediate
morphology at interface)
Mixed hepatobiliary carcinoma,
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CK19+
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Fig. 2. (a) HCC with classic histology (left) and with immunohistochemical expression of CK19 (right). 
(b) Emerging classification of primary liver cancer based on tumor cell differentiation by morphology 
and immunophenotype (adapted and modified from Roncalli et al.Q22, Q23 [46]).
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